Cooper Financial Group Buys New Shares in Qiagen N.V. $QGEN

Cooper Financial Group bought a new stake in Qiagen N.V. (NYSE:QGENFree Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,278 shares of the company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Voya Investment Management LLC increased its position in shares of Qiagen by 52.3% in the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company’s stock valued at $9,845,000 after acquiring an additional 84,332 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Qiagen in the fourth quarter valued at about $202,000. GAMMA Investing LLC increased its position in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after acquiring an additional 1,425 shares during the last quarter. Cetera Investment Advisers grew its holdings in Qiagen by 23.2% during the first quarter. Cetera Investment Advisers now owns 13,917 shares of the company’s stock worth $551,000 after purchasing an additional 2,620 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Qiagen by 69.4% during the first quarter. AQR Capital Management LLC now owns 178,425 shares of the company’s stock worth $7,164,000 after purchasing an additional 73,122 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of Qiagen stock opened at $46.26 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of 27.33, a P/E/G ratio of 2.44 and a beta of 0.66. The company’s fifty day moving average is $47.53 and its 200 day moving average is $45.19.

Qiagen (NYSE:QGENGet Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter in the previous year, the firm posted $0.55 earnings per share. Qiagen’s revenue for the quarter was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on QGEN shares. Cowen reiterated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Bank of America lifted their price target on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. Wall Street Zen cut Qiagen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 11th. Barclays set a $53.00 price target on Qiagen and gave the stock an “overweight” rating in a report on Thursday. Finally, UBS Group lifted their price target on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Qiagen presently has a consensus rating of “Hold” and a consensus price target of $49.40.

Read Our Latest Stock Report on QGEN

Qiagen Company Profile

(Free Report)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Recommended Stories

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGENFree Report).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.